New Pregnancy Assay Receives CE Marking and FDA Clearance
|
By LabMedica International staff writers Posted on 20 Jan 2014 |
|
![Image: The new high standard \"Access Total βhCG (5th IS)\" assay for pregnancy determination from Beckman Coulter Diagnostics (Photo courtesy of Beckman Coulter).](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2014-01-20/MMS-003.gif "Image: The new high standard \\"Access Total βhCG (5th IS)\\" assay for pregnancy determination from Beckman Coulter Diagnostics (Photo courtesy of Beckman Coulter).")
Image: The new high standard \"Access Total βhCG (5th IS)\" assay for pregnancy determination from Beckman Coulter Diagnostics (Photo courtesy of Beckman Coulter).
The approved new pregnancy determination assay features a broad dynamic range and is the first to standardize to the World Health Organization's latest international standard.
To help move reproductive health management forward, Beckman Coulter Diagnostics of Beckman Coulter (Brea, CA, USA) has received the CE marking and US Food and Drug Administration (FDA) 510(k) clearance for its new "Access Total βhCG (5th IS)" assay. It is the first βhCG assay standardized to the highly purified World Health Organization (WHO) 5th International Standard (IS) for glycoprotein chorionic gonadotropin. The βhCG assay is critical in routine and emergency diagnosis as it is frequently ordered on women of childbearing-age who require treatment, which could potentially be harmful to a fetus. The expanded utility of the assay has also been CE Mark approved for Down syndrome assessment during pregnancy.
“As the first manufacturer to standardize to the WHO 5th IS, the new βhCG assay is an example of Beckman Coulter’s continuing dedication to lead the way in this important diagnostic field,” said John Blackwood, senior vice president of Product Management for Beckman Coulter Diagnostics; “The new assay is just one example of the innovations that comprise Beckman Coulter’s reproductive health portfolio—the most comprehensive immunoassay reproductive panel available on the market.”
The assay features a broad dynamic range with automatic onboard dilution capability, reducing the need for manual sample dilutions. As a part of the standardization, reference ranges have been updated to include additional populations that include women over the age of 40, postmenopausal women, and men. Additionally, in response to changing laboratory environments and the challenges faced in collecting serum samples, Beckman Coulter has further improved the Total βhCG (5th IS) to make it more resilient to preanalytical factors.
"Access" reproductive solutions are part of a comprehensive assay menu featured on the Access and UniCel Immunoassay Systems.
Related Links:
Beckman Coulter
To help move reproductive health management forward, Beckman Coulter Diagnostics of Beckman Coulter (Brea, CA, USA) has received the CE marking and US Food and Drug Administration (FDA) 510(k) clearance for its new "Access Total βhCG (5th IS)" assay. It is the first βhCG assay standardized to the highly purified World Health Organization (WHO) 5th International Standard (IS) for glycoprotein chorionic gonadotropin. The βhCG assay is critical in routine and emergency diagnosis as it is frequently ordered on women of childbearing-age who require treatment, which could potentially be harmful to a fetus. The expanded utility of the assay has also been CE Mark approved for Down syndrome assessment during pregnancy.
“As the first manufacturer to standardize to the WHO 5th IS, the new βhCG assay is an example of Beckman Coulter’s continuing dedication to lead the way in this important diagnostic field,” said John Blackwood, senior vice president of Product Management for Beckman Coulter Diagnostics; “The new assay is just one example of the innovations that comprise Beckman Coulter’s reproductive health portfolio—the most comprehensive immunoassay reproductive panel available on the market.”
The assay features a broad dynamic range with automatic onboard dilution capability, reducing the need for manual sample dilutions. As a part of the standardization, reference ranges have been updated to include additional populations that include women over the age of 40, postmenopausal women, and men. Additionally, in response to changing laboratory environments and the challenges faced in collecting serum samples, Beckman Coulter has further improved the Total βhCG (5th IS) to make it more resilient to preanalytical factors.
"Access" reproductive solutions are part of a comprehensive assay menu featured on the Access and UniCel Immunoassay Systems.
Related Links:
Beckman Coulter
New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Electrolyte Analyzer
BKE-B
New
Urine Analyzer
respons® UDS100
Latest Immunology News
- Study Finds Influenza Often Undiagnosed in Winter Deaths
- Combined Screening Approach Identifies Early Leprosy Cases
- Antibody Blood Test Identifies Active TB and Distinguishes Latent Infection
- FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas
- Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
- Microfluidic Chip Detects Cancer Recurrence from Immune Response Signals
- Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response
- Immune Signature Identified in Treatment-Resistant Myasthenia Gravis
- New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer
- Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
- Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
- Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
- Blood Test Could Identify Colon Cancer Patients to Benefit from NSAIDs
- Blood Test Could Detect Adverse Immunotherapy Effects
- Routine Blood Test Can Predict Who Benefits Most from CAR T-Cell Therapy
- New Test Distinguishes Vaccine-Induced False Positives from Active HIV Infection
Channels
Clinical Chemistry
view channel
Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms
Alzheimer's disease often advances silently for years, making timely risk stratification difficult in routine practice. Current approaches to detect pathology can involve lumbar puncture or positron emission... Read more
Study Finds ApoB Testing More Effective Than LDL for Guiding Lipid Therapy
Routine blood tests that measure low-density lipoprotein (LDL), commonly known as “bad” cholesterol, are widely used to guide lipid-lowering therapy, but they do not always provide a complete picture of... Read more
AI-Enabled POC Test Quantifies Multiple Cardiac Biomarkers
Cardiovascular diseases are a leading cause of death, responsible for nearly 20 million deaths each year. Timely triage of myocardial infarction and heart failure hinges on rapid cardiac biomarker measurement,... Read more
Next Generation Automated Analyzers Increase Throughput for Clinical Chemistry and Electrolyte Testing
Clinical laboratories continue to face staffing shortages, limited space, and growing test volumes that pressure chemistry and electrolyte workflows. Maintaining rapid turnaround times increasingly depends... Read moreMolecular Diagnostics
view channel
Blood-Based Epigenetic Signals Enable Osteosarcoma Disease Monitoring
Osteosarcoma is a rare but aggressive pediatric bone cancer where recurrence and metastasis remain difficult to detect early. Imaging-based surveillance can miss small lesions and exposes children to repeated... Read more
Host–Virus Genetic Interactions Drive Nasopharyngeal Cancer Risk
Epstein–Barr virus (EBV) infects more than 95% of adults worldwide, yet only a small fraction develops EBV‑associated cancers such as nasopharyngeal carcinoma. Explaining this divergence requires understanding... Read more
Hematology
view channel
Routine Blood Test Parameters Link Anemia to Cancer Risk and Mortality
Anemia detected in routine care can signal underlying pathology and is frequently encountered in adults. Because it is defined by hemoglobin levels below the normal range, it is often evaluated with red... Read more
Prognostic Tool Guides Personalized Treatment in Rare Blood Cancer
Chronic myelomonocytic leukemia (CMML) is a rare blood cancer in which acquired genetic mutations in bone marrow stem cells drive disease. Stem cell transplantation is the only curative option but carries... Read more
Microbiology
view channel
Rapid Color Test Stratifies Virulent and Resistant Staph Strains
Staphylococcus aureus (golden staph) remains a leading cause of infection-related mortality worldwide, responsible for more than a million deaths each year. Rapidly distinguishing highly virulent or a... Read more
Syndromic Panel Enables Rapid Identification of Bloodstream Infections
Bloodstream infections require rapid identification of causative pathogens and resistance determinants to guide therapy, yet laboratories often face pressure to deliver clinically relevant results quickly... Read more
RNA-Based Workflow Identifies Active Skin Microbes for Dermatology Research
Human skin carries diverse microbial communities that influence barrier function and inflammation, yet identifying which organisms are metabolically active has been challenging. DNA-based surveys catalog... Read more
Cost-Effective Sampling and Sequencing Workflow Identifies ICU Infection Hotspots
Intensive care units face persistent threats from hospital-acquired infections, increasingly driven by drug-resistant bacteria. Rapidly pinpointing environmental reservoirs and transmission hotspots remains... Read morePathology
view channel
Biomarker Predicts Immunotherapy Response and Prognosis in Colorectal Cancer
Colorectal cancer is common and often lethal, and therapeutic decision-making is complicated by heterogeneous tumor microenvironments. Immunotherapy benefits only a small subset of patients, around 5%,... Read more
Collaboration Applies AI Pathology to Predict Response to Antibody-Drug Conjugates
Antibody-drug conjugates (ADC) are reshaping oncology, yet scalable biomarkers that reliably predict which patients will benefit remain limited as treatment regimens and combinations grow more complex.... Read more
Technology
view channel
AI Tool Predicts Non-Response to Targeted Therapy in Colorectal Cancer
Advanced bowel cancer remains difficult to treat, and many patients receive targeted therapies that do not help them but still cause harm. Clinicians need reliable ways to identify likely responders before... Read more
Integrated System Streamlines Pre-Analytical Workflow for Molecular Testing
Pre-analytical variation remains a leading source of inconsistent molecular test results and added costs, particularly when laboratories rely on multiple instruments and protocols. Standardizing nucleic... Read more
Industry
view channel
Partnership Expands Ultrasensitive WGS Assay for for Hematologic Malignancies and MRD Monitoring
Tempus AI and Predicta Biosciences announced the commercial expansion of a co-branded whole‑genome sequencing assay GenoPredicta, which is intended for comprehensive genomic characterization of hematologic... Read more
